Fatimah Manzoor, MD
Internal Medicine · Gainesville, GANPI 1750502357
Payments from drug & device makers
Across 145 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$315
- Novo Nordisk$285
- AstraZeneca$254
- Lilly USA, LLC$228
- GSK$195
- AbbVie$141
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,48699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $315 |
| Novo Nordisk | 22 | $285 |
| AstraZeneca | 12 | $254 |
| Lilly USA, LLC | 15 | $228 |
| GSK | 10 | $195 |
| AbbVie | 8 | $141 |
| Sanofi-aventis U.S. LLC | 9 | $130 |
| Astellas Pharma US Inc | 7 | $116 |
| Corcept Therapeutics | 6 | $101 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Amgen | 2 | $65 |
| Inspire Medical Systems, Inc. | 1 | $64 |
| Abbott | 4 | $55 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $49 |
| Aytu Biopharma, Inc. | 1 | $39 |
| Mylan Specialty L.p. | 2 | $38 |
| Boston Scientific | 2 | $36 |
| Johnson & Johnson | 1 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| Bayer | 2 | $26 |
| Tris Pharma Inc | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Dexcom, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Exact Sciences | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Nevro Corp. | 1 | $11 |
How this compares
$2,500 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 111 | $101,350 |
| TrulicityDulaglutide | 53 | $80,974 |
| OzempicSemaglutide | 63 | $78,130 |
| JanuviaSitagliptin Phosphate | 77 | $64,520 |
| EliquisApixaban | 43 | $53,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $37,886 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $36,563 |
| FarxigaDapagliflozin Propanediol | 23 | $31,925 |
| JardianceEmpagliflozin | 25 | $29,177 |
| MyrbetriqMirabegron | 44 | $25,725 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $16,347 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $15,029 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $14,657 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $14,505 |
| Novolog FlexpenInsulin Aspart | 60 | $13,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $22 | $130,527136 claims |
| Lilly USA, LLCTrulicity, Humalog | $228 | $85,70068 claims |
| Novo NordiskOzempic, Novolog | $285 | $83,59990 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $195 | $59,40096 claims |
| PfizerEliquis, Premarin | $315 | $57,52557 claims |
| AstraZenecaFarxiga, Symbicort | $254 | $35,29839 claims |
| Astellas Pharma US IncMyrbetriq | $116 | $25,72544 claims |
| AbbVieSynthroid | $141 | $5,80467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Gainesville
- Christopher RecknorGainesville$9.2M
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.